- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 28.01. | Intensity Therapeutics' Sarkom-Studie schreitet nach Überprüfung voran | 3 | Investing.com Deutsch | ||
| 28.01. | Intensity Therapeutics' sarcoma trial proceeds after review | 1 | Investing.com | ||
| INTENSITY THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| 28.01. | Intensity Therapeutics Inc.: Drug Monitoring Committee Authorizes Continuation of Intensity Therapeutics' Ongoing Global Randomized Phase 3 Sarcoma Trial ("INVINCIBLE-3 Study") Following Periodic Review | 74 | PR Newswire | INVINCIBLE-3 Study continues to recruit patients with leiomyosarcoma, liposarcoma and undifferentiated pleomorphic sarcoma; authorizations for the INVINCIBLE-3 Study... ► Artikel lesen | |
| 13.12.24 | Intensity Therapeutics files to sell 1.24M shares of common stocks by selling shareholders | 1 | Seeking Alpha | ||
| 13.12.24 | INTENSITY THERAPEUTICS, INC. - S-1, General form for registration of securities | - | SEC Filings | ||
| 22.11.24 | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | - | SEC Filings | ||
| 21.11.24 | Intensity Therapeutics sichert sich 3 Millionen US-Dollar durch Aktienemission | 1 | Investing.com Deutsch | ||
| 21.11.24 | Intensity Therapeutics secures $3 million in stock offering | 1 | Investing.com | ||
| 14.11.24 | Intensity Therapeutics GAAP EPS of -$0.25 | 1 | Seeking Alpha | ||
| 13.11.24 | Intensity Therapeutics Inc.: Intensity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update | 242 | PR Newswire | First patient dosed in randomized, Phase 2 study in presurgical triple negative breast cancer
SHELTON, Conn., Nov. 13, 2024 /PRNewswire/ -- Intensity Therapeutics... ► Artikel lesen | |
| 13.11.24 | INTENSITY THERAPEUTICS, INC. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 24.10.24 | Intensity Therapeutics grants stock options to top executives | 1 | Investing.com | ||
| 23.10.24 | INTENSITY THERAPEUTICS, INC. - 8-K, Current Report | 1 | SEC Filings | ||
| 08.08.24 | Intensity Therapeutics Inc.: Intensity Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update | 147 | PR Newswire | First patient dosed in global randomized, Phase 3 study in metastatic soft tissue sarcoma
Collaboration agreement with The Swiss Group for Clinical Cancer Research SAKK ("SAKK") to conduct a Phase... ► Artikel lesen | |
| 09.07.24 | Intensity Therapeutics Inc.: Intensity Therapeutics, Inc. Announces First Patient Dosed in its Global Randomized, Phase 3 Study (INVINCIBLE-3) in Metastatic Soft Tissue Sarcoma | 99 | PR Newswire | Testing the efficacy and safety of our lead product candidate, INT230-6, as Monotherapy Compared with Systemic U.S. Standard-of-Care Chemotherapy
SHELTON, Conn., July 9, 2024 /PRNewswire/ -- Intensity... ► Artikel lesen | |
| 09.05.24 | Intensity Therapeutics Inc.: Intensity Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update | 204 | PR Newswire | INT230-6, Intensity's lead drug candidate, continues to advance into late-stage clinical programs in sarcoma and breast cancer
Cash and investments of $10.5 million expected to fund operations through... ► Artikel lesen | |
| 14.03.24 | Intensity Therapeutics Inc.: Intensity Therapeutics Reports Full Year 2023 Financial Results and Provides Corporate Update | 207 | PR Newswire | INT230-6, Intensity's lead drug candidate, advances into late-stage clinical programs in sarcoma and breast cancer
Year-end cash and investments of $14.8 million expected to fund operations through... ► Artikel lesen |
17 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 107,60 | +0,75 % | Achtung - BioTech startet durch! Evotec, Vidac Pharma, BioNTech und Novo Nordisk im Fokus | Mit täglich neuen Index-Höchstständen und riesigen Börsenumsätzen, steht der BioTech-Sektor nun seit einigen Wochen auch wieder im Fokus. Bei Evotec dreht sich das Personalkarussell weiter, BioNTech... ► Artikel lesen | |
| NOVAVAX | 7,470 | -0,70 % | Novavax Aktie: Erfolgskurs stabilisiert sich! | Der Impfstoffhersteller Novavax verzeichnete im vierten Quartal 2024 einen deutlichen Rückgang des Nettoverlustes auf 81,03 Millionen Dollar oder 0,51 Dollar pro Aktie, verglichen mit einem Verlust... ► Artikel lesen | |
| CRISPR THERAPEUTICS | 40,400 | -5,16 % | Prediction: CRISPR Therapeutics Will Beat the Market. Here's Why | ||
| EDITAS MEDICINE | 1,731 | +2,76 % | Editas Medicine, Inc.: Editas Medicine Highlights New In Vivo Preclinical Proof of Concept Data, Anticipated 2025 Key Milestones, and Three-year Strategic Priorities | Achieved in vivo preclinical proof of concept of editing hematopoietic stem cells in non-human primates as a key step toward developing a novel in vivo treatment for sickle cell disease and beta thalassemia... ► Artikel lesen | |
| GINKGO BIOWORKS | 8,150 | +6,54 % | Ginkgo Bioworks Reports Fourth Quarter and Full Year 2024 Financial Results | Ginkgo provides update on its restructuring process including significant improvement in cash flow in the fourth quarter, completion of site consolidation and an... ► Artikel lesen | |
| NOVOCURE | 18,150 | +3,39 % | Novocure Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Company Update | Full year 2024 net revenues of $605 million and fourth quarter net revenues of $161 million Optune Lua® received FDA approval for the treatment of metastatic non-small cell lung cancer, commercial... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,490 | 0,00 % | Adaptimmune Therapeutics Aktie: Vertrauensbruch im Anmarsch? | Die Adaptimmune Therapeutics Aktie verzeichnet zum 01. März 2025 einen stabilen Kurs von 0,52 EUR, bleibt jedoch unter Druck. Im vergangenen Monat musste das biopharmazeutische Unternehmen einen Rückgang... ► Artikel lesen | |
| ADVERUM BIOTECHNOLOGIES | 3,880 | 0,00 % | Adverum Biotechnologies, Inc.: Adverum Biotechnologies Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | REDWOOD CITY, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM) today announced that the Compensation Committee of Adverum's Board of Directors granted inducement... ► Artikel lesen | |
| QIAGEN | 36,890 | +0,16 % | Qiagen NV-Aktie kann Vortagsniveau nicht halten (37,31 €) | Im Minus liegt zur Stunde die Aktie von Qiagen NV . Der jüngste Kurs betrug 37,31 Euro. Für das Wertpapier von Qiagen NV steht gegenwärtig ein Verlust von 1,39 Prozent zu Buche. Die Aktie verbilligte... ► Artikel lesen | |
| RECURSION PHARMACEUTICALS | 6,590 | 0,00 % | Recursion Pharmaceuticals: Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2024 Financial Results | Reported promising safety and preliminary efficacy data for REC-617, an oral CDK7 inhibitor, and met primary endpoints and demonstrated encouraging trends in efficacy for REC-994 in cerebral cavernous... ► Artikel lesen | |
| EVOTEC | 8,150 | -0,43 % | Evotec Aktie: Wechselwirkungen im internationalen Kontext | Die Evotec-Aktie verzeichnete am Handelstag einen bemerkenswerten Aufschwung und kletterte im XETRA-Handel um 5,3 Prozent auf 8,97 Euro. Das Handelsvolumen erreichte dabei 475.841 Aktien, wobei das... ► Artikel lesen | |
| TEMPUS AI | 50,94 | 0,00 % | Palantir | Hims | Tempus AI - DeepSeek kurbelt Chipnachfrage von Nvidia an! | Markus Weingran - Mein Tipp: SMARTBROKER+: https://broker-tipp.de/ (Werbung) Willkommen bei der Börsenlounge mit Markus Weingran. Die Themen heute: Palantir | Hims | Tempus AI - DeepSeek kurbelt Chipnachfrage... ► Artikel lesen | |
| EDGEWISE THERAPEUTICS | 25,530 | -2,41 % | Edgewise Therapeutics, Inc. - S-8, Securities to be offered to employees in employee benefit plans | ||
| SPRINGWORKS THERAPEUTICS | 53,32 | 0,00 % | SpringWorks Therapeutics, Inc.: SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights Recent Business Updates | - Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product revenues, respectively - - Received FDA approval of GOMEKLI (mirdametinib)... ► Artikel lesen | |
| ADMA BIOLOGICS | 15,840 | 0,00 % | ADMA BIOLOGICS, INC. Q4 Earnings Summary |
Das Unternehmen INTENSITY THERAPEUTICS INC kann der Branche Biotechnologie zugeordnet werden. Der aktuelle Kurs liegt bei 2,200 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu INTENSITY THERAPEUTICS INC finden Sie auf Wallstreet Online.
